(s)-2-((2r,3r)-3-((s)-1-((5s,8s,11s,12r)-11 -结构式
|
常用名 | (s)-2-((2r,3r)-3-((s)-1-((5s,8s,11s,12r)-11 - | 英文名 | (2R,3R)Methyl-2-(N-((2S,3R)-3-((9S)-9-((S)-2-((((9H-Fluoren-9-Yl)Methoxy)Carbonyl)(Methyl)Amino)-3-Methylbutanamido)-3-Methoxy-5,10-Dimethyl-4-(Methylamino)-8-Oxoundecanoyl)Pyrrolidin-2-Yl)Propionamido)-3-Methoxy-2-Methyl-3-Phenylpropanoate |
|---|---|---|---|---|
| CAS号 | 863971-38-4 | 分子量 | 968.23 | |
| 密度 | 1.2±0.1 g/cm3 | 沸点 | 1029.7±65.0 °C at 760 mmHg | |
| 分子式 | C55H77N5O10 | 熔点 | N/A | |
| MSDS | N/A | 闪点 | 576.5±34.3 °C |
用途Fmoc-MMAF-OMe 是带有 Fmoc 保护基团的抗癌剂和微管蛋白聚合 (tubulin polymerization) 抑制剂。Fmoc-MMAF-OMe 的有效成分 MMAF (HY-15579) 是经典的抗体偶联药物 (ADCs) 的细胞毒性 (ADC Cytotoxin) 成分。 |
| 中文名 | (s)-2-((2r,3r)-3-((s)-1-((5s,8s,11s,12r)-11 - |
|---|---|
| 英文名 | L-Phenylalanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-L-valyl-(3R,4S,5S)-3-methoxy-5-methyl-4-(methylamino)heptanoyl-(αR,βR,2S)-β-methoxy-α-methyl-2-pyrrolidinepropanoyl-, methyl ester |
| 中文别名 | (2R,3R)甲基-2-(N-((2S,3R)-3-((9S)-9-((S)-2-((((9H-芴-9-基)甲氧基)羰基)(甲基)氨基)-3-甲基丁酰氨基)-3-甲氧基5,10-(甲基氨基)-8-氧代十一烷酰基)吡咯烷-2-基)丙酰胺基)-3-甲氧基-2-甲基-3-苯基丙酸酯 |
| 英文别名 | 更多 |
| 密度 | 1.2±0.1 g/cm3 |
|---|---|
| 沸点 | 1029.7±65.0 °C at 760 mmHg |
| 分子式 | C55H77N5O10 |
| 分子量 | 968.23 |
| 闪点 | 576.5±34.3 °C |
| 精确质量 | 967.567017 |
| LogP | 9.14 |
| 蒸汽压 | 0.0±0.3 mmHg at 25°C |
| 折射率 | 1.550 |
| 储存条件 | 室温 |
| MFCD28385900 |
| L-Valinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-2-methoxy-4-[(2S)-2-[(1R,2R)-1-methoxy-3-[[(1S)-2-methoxy-2-oxo-1-(phenylmethyl)ethyl]amino]-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl- |
| N-[(9H-Fluoren-9-ylmethoxy)carbonyl]-N-methyl-L-valyl-N-[(3R,4S,5S)-3-methoxy-1-{(2S)-2-[(1R,2R)-1-methoxy-3-{[(2S)-1-methoxy-1-oxo-3-phenyl-2-propanyl]amino}-2-methyl-3-oxopropyl]-1-pyrrolidinyl}-5-methyl-1-oxo-4-heptanyl]-N-methyl-L-valinamide |
